Figure 5
From: Designed hybrid TPR peptide targeting Hsp90 as a novel anticancer agent
Antitumor activity of hybrid Antp-TPR peptide in vivo. (A) BXPC3 pancreatic cancer cells were implanted subcutaneously into athymic nude mice. Intravenous injection of either PBS (control) or Antp-TPR peptide (1 or 5 mg/kg) was provided from day 4 as indicated by the arrows. Each group had six animals (n = 6), and experiments were repeated twice. Data are expressed as mean ± SD. (B) Loss of Hsp90 client protein (CDK4) in tumors treated with Antp-TPR peptide in vivo. BXPC3 tumors from saline or Antp-TPR peptide (5 mg/kg) treated animals were harvested at the end of treatment and analyzed with antibody to CDK4 by immunohistochemistry. Scale bars, 25 μm. (C) Histologic examination after treatment with Antp-TPR hybrid peptide. Images (x400 magnification) of liver, kidney, and lung from mice after treatment with saline (control), or Antp-TPR peptide (5 mg/kg) nine times were obtained by staining with hematoxylin and eosin (H & E).